查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1609977

個人化醫療生物標記市場規模、佔有率、趨勢分析報告：按應用、適應症、地區、細分市場預測，2025-2030

Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Report By Application (Early Detection, Treatment Selection, Monitoring), By Indication (Oncology, Neurology), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

個人化醫療生物標記市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球個人化醫療生物標記市場規模將達到471.6億美元，2025年至2030年複合年成長率為13.6%。

這種成長歸因於認知的提高、預後的重要性和劑量選擇。此外，個人化醫療生物標記是選擇患者並為正確患者提供正確治療的重要工具，進一步推動了對個人化醫療生物標記的需求。

生物標記是獨特的分析物，可用於診斷、預測、改善治療結果並指導治療決策。生物標記對於個人化醫療至關重要。利用生物標記改善患者預後的臨床試驗十分活躍，臨床應用正迅速擴大。使用生物標記的個人化醫療的發展預計將為所有患者創造有效且安全的治療方法。這將為癌症等慢性病晚期患者提供極大的緩解，進一步推動市場成長。例如，2022 年 8 月，VENTANA MMR RxDx Panel 獲得 FDA核准，這是第一個基於 IHC 的檢測方法，用於識別晚期癌症患者是否需要Pembrolizumab治療。

早期檢測/篩檢生物標記可以預測治療前患者群體的疾病結果。它還透過選擇更有可能對治療產生反應的患者來幫助豐富臨床試驗。例如，Oncotype Dx 是 Genomic Health 開發的診斷測試。此測試檢查 21 個基因，有助於預測患者在初次治療後乳癌復發的可能性。 2022 年 4 月，ASCO 指引更新，建議早期乳癌患者使用 Oncotype DX 測試來指南治療決策。

此外，生物標記還具有預測和預後效用，可幫助預測健康狀況的發生。例如，前列腺特異性抗原用於預測前列腺癌患者的存活率。 CRP 用於預測乳癌的無疾病存活率，並作為心血管疾病的危險因子。血清 LDH 有助於預測轉移性腦瘤的存活率。同樣，CA125 有助於預測子宮癌患者的轉移性疾病。

此外，個人化醫療生物標記行業的主要企業都致力於擴大可用於廣泛應用的產品並將其推向市場。例如，2021 年 10 月，安捷倫科技公司的 Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis) 獲得 FDA核准，用於識別乳癌復發高風險的患者。

個性化醫療生物標記市場報告亮點

  • 透過應用，由於需要早期患者治療，早期檢測/篩檢預計將以最快的複合年成長率成長。
  • 有跡象表明，由於癌症盛行率上升以及 FDA 批准的個人化癌症生物標記測試的廣泛使用，腫瘤學將在 2024 年佔據最大的市場佔有率。
  • 由於醫療基礎設施改善、目標疾病盛行率上升以及政府對生物標記創新的資助增加，北美佔據了最大的市場佔有率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章個人化醫療生物標記市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 個人化醫療生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章個人化醫療生物標記市場：應用估計和趨勢分析

  • 細分儀表板
  • 個人化醫療生物標記市場：適應症變化分析
  • 個人化醫療生物標記市場前景：按適應症分類
  • 2018-2030年市場規模/預測與趨勢分析
  • 早期發現/篩檢
  • 診斷
  • 治療選擇
  • 監視

第5章個人化醫療生物標記市場：適應症估計與趨勢分析

  • 細分儀表板
  • 個人化醫療生物標記市場：生物標記波動分析
  • 個人化醫療生物標記市場：生物標記展望
  • 2018-2030年市場規模/預測與趨勢分析
  • 腫瘤學
  • 神經病學
  • 糖尿病
  • 自體免疫疾病
  • 心臟病學
  • 其他

第6章個人化醫療生物標記市場：區域估計與趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 公司分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 2024 年企業市場佔有率分析
  • 公司簡介
    • Laboratory Corporation of America Holding
    • Quest Diagnostics Incorporated
    • Agilent Technologies, Inc
    • Genome Medical, Inc
    • Thermo Fisher Scientific, Inc
    • Coriell Life Sciences
    • NeoGenomics Laboratories
    • FOUNDATION MEDICINE, INC
    • Illumina, Inc
    • Guardant Health
Product Code: GVR-4-68039-996-3

Personalized Medicine Biomarkers Market Growth & Trends:

The global personalized medicine biomarkers market size is estimated to reach USD 47.16 billion by 2030, registering a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.

Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.

Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.

Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.

Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.

Personalized Medicine Biomarkers Market Report Highlights:

  • Based on application, the early detection/screening segment is expected to grow at the fastest CAGR owing to the need to provide early treatment to patients.
  • By indication, the oncology segment held the largest market share in 2024, owing to the rising prevalence of cancer and the wide availability of FDA-approved personalized biomarkers tests for cancer
  • North America held the largest market share attributable to the presence of improved healthcare infrastructure, rising prevalence of target diseases, and increasing government funding for innovation in biomarkers.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Application
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Indication outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Personalized Medicine Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Rising awareness and importance of predicting prognosis and selection of dose
      • 3.2.1.3. Need to provide early diagnosis and treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory & reimbursement hurdles
  • 3.3. Personalized Medicine Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Personalized Medicine Biomarkers Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Personalized Medicine Biomarkers Market: Indication Movement Analysis
  • 4.3. Personalized Medicine Biomarkers Market by Indication Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Early Detection/Screening
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Diagnosis
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.7. Treatment Selection
    • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.8. Monitoring
    • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Personalized Medicine Biomarkers Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Personalized Medicine Biomarkers Market: Biomarker Movement Analysis
  • 5.3. Personalized Medicine Biomarkers Market by Biomarker Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Oncology
    • 5.5.1. By Type Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.1.1. Breast Cancer
        • 5.5.1.1.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.1.2. Lung Cancer
        • 5.5.1.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.1.3. Colon Cancer
        • 5.5.1.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.1.4. Others
        • 5.5.1.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.5.2. By Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.2.1. Circulating Tumor Cells
        • 5.5.2.1.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.2.2. Circulating Cell-free DNA
        • 5.5.2.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.2.3. Extracellular Vesicles
        • 5.5.2.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.5.2.4. Other Circulating Biomarkers
        • 5.5.2.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Neurology
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Diabetes
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.8. Autoimmune Diseases
    • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.9. Cardiology
    • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Personalized Medicine Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company overview
    • 7.4.1. Laboratory Corporation of America Holding
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Quest Diagnostics Incorporated
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Agilent Technologies, Inc
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Genome Medical, Inc
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Thermo Fisher Scientific, Inc
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Coriell Life Sciences
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. NeoGenomics Laboratories
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. FOUNDATION MEDICINE, INC
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Illumina, Inc
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Guardant Health
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 4 Global personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 5 North America personalized medicine biomarkers, by region, 2018 - 2030 (USD Billion)
  • Table 6 North America personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 7 North America personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 8 U.S. personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 9 U.S. personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 10 Canada personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 11 Canada personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 12 Mexico personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 13 Mexico personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 14 Europe personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 16 Europe personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 17 UK personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 18 UK personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 19 Germany personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 20 Germany personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
  • Table 21 France personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 22 France personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
  • Table 23 Italy personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 24 Italy personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 25 Spain personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 26 Spain personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 27 Denmark personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 28 Denmark personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
  • Table 29 Norway personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 30 Norway personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 31 Sweden personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 32 Sweden personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 36 Japan personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 37 Japan personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 38 China personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 39 China personalized medicine biomarkers, by indication 2018 - 2030 (USD Billion)
  • Table 40 India personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 41 India personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 42 Australia personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 43 Australia personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 44 South Korea personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 45 South Korea personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 46 Thailand personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 47 Thailand personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 48 Latin America personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 50 Latin America personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 51 Brazil personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 52 Brazil personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 53 Argentina personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 54 Argentina personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 55 Middle East & Africa personalized medicine biomarkers, by country, 2018 - 2030 (USD Billion)
  • Table 56 Middle East & Africa personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 57 Middle East & Africa personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 58 South Africa personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 59 South Africa personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 62 UAE personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 63 UAE personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait personalized medicine biomarkers, by application, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait personalized medicine biomarkers, by indication, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Personalized medicine biomarkers market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Personalized medicine biomarkers market: Application outlook and key takeaways
  • Fig. 12 Early detection/screening market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Diagnosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Treatment selection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Monitoring circulating biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Personalized medicine biomarkers market: Indication outlook and key takeaways
  • Fig. 17 Personalized medicine biomarkers market: Indication movement analysis
  • Fig. 18 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Autoimmune diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Personalized Medicine Biomarkers Market: Regional outlook and key takeaways
  • Fig. 25 Breast cancer liquid biopsy: Regional movement analysis
  • Fig. 26 Personalized medicine biomarkers market: regional key takeaways (USD Billion)
  • Fig. 27 Personalized medicine biomarkers market: regional outlook, 2023 & 2030 (USD Billion)
  • Fig. 28 North America personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 U.S. personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Canada personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Mexico personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Europe personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 UK personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 Germany personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 France personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Spain personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Italy personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Norway personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Denmark personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Sweden personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Asia Pacific personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 42 China personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 Japan personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 India personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 South Korea personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 Australia personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Thailand personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Latin America personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Brazil personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 Argentina personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Middle East and Africa personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 South Africa personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Saudi Arabia personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 UAE personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Kuwait personalized medicine biomarkers market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 List of key emerging company's/technology disruptors/innovators